TITLE

Trattamento conservativo e sopravvivenza in pazienti affetti da urotelioma vescicale T1G3. Quando proporlo e quando la cistectomia?

AUTHOR(S)
Ruggirello, A.; Serretta, V.; Passalacqua, D.; Zaccone, V.; Daricello, M.; Aragona, F.; Allegro, R.; Melloni, D.
PUB. DATE
October 2009
SOURCE
Urologia;2009, Vol. 76 Issue S-15, pS31
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
INTRODUCTION. Conservative management is not applicable to all T1G3 tumors. The appropriate treatment should minimize mortality while assuring reduced morbidity and good quality of life. Several attempts have been done to identify categories of T1G3 patients at higher risk. The role of biologic markers is unclear and the prognostic risk factors are mainly clinical. The proper time to abandon the conservative approach in favor of cystectomy is still object of debate. OBJECTIVES. The aim of the present study is to assess the clinical tumor features showing a detrimental effect on survival, identify the clinical risk factors impacting survival in patients undergoing conservative management of T1G3 bladder tumor, and to analyze the prognostic role of recurrence. METHODS. The present analysis is extended to 236 patients with T1G3 bladder tumors treated by TUR plus intravesical therapy between 1976 and 2005. Patients with previous T1G3, Tis, more than 3 tumors or greater than 3cm were excluded. Urinary cytology was obtained within 30 days after TUR. Since 2000 re-TUR has been performed. A sequential combination of mitomycin-C (30mg/30ml) and epirubicin (50mg/50ml) was adopted in 106 patients (44.9%). BCG or other agents were given intravesically in 85 (36.0%) and 38 (16.1%) patients, respectively. Seven (3%) patients refused intravescical therapy. In the case of Ta-TI recurrence, TUR and one year of adjuvant intravesical therapy were repeated. Patients went off study if Tis, T1G3 or T-category tumor over Ti were detected. Age, previous history, number of tumors, re-TUR, adjuvant therapy, recurrence and progression were considered for survival analysis. RESULTS. Tumors were primary in 177 (75.3%) and single in 144 (61.5%) cases. At a mean follow-up of 52 months (range: 3-246 months), 116 patients (49.2%) relapsed. The recurring tumor was Ti in 47(40.5%) cases and T1G3 in 33 (28.4%). In 11 additional patients (9.5%) a Tis was detected. Twenty-five patients (10.6%) progressed and 15 patients (6.4%) underwent cystectomy. Median overall survival was 167 months. The 5-year progression-free survival rate was 87.8%. Thirty-two patients (13.6%) died, 22 (9.3%) for bladder cancer. A higher mortality was detected in recurrent (p= 0.002) and multiple (p=0.009) tumors undergoing conservative management. Survival was decreased by NM! recurrence (p<0.0001) and by progression (p=0.009). No statistical significant difference in survival was evident in relation to the grade and stage of the recurrent tumor. CONCLUSIONS. Previous positive history and multiplicity are relevant risk factors for survival in patients affected by T1G3 NMI TCCB conservatively treated. Survival is decreased if conservative management is not given up at the time of NMI recurrence, independently from its grade and stage.
ACCESSION #
49137301

Tags: BLADDER -- Cancer -- Patients;  BCG vaccines -- Therapeutic use;  CHEMOTHERAPY;  THERAPEUTICS;  MITOMYCIN C;  ANTINEOPLASTIC antibiotics

 

Related Articles

  • Bladder Ca guidelines support BCG, mitomycin Tx. Overmyer, Mac // Urology Times;Dec99, Vol. 27 Issue 12, p1 

    Reports that intravesical bacillus Calmette-Guerin and mitomycin are the preferred therapies following removal of T1 and high-grade Ta bladder cancer tumors. Guidelines from the American Urological Association; Lack of optimal dosages recommended for intravesical therapy and immunotherapy.

  • Effective management of superficial bladder cancer. Lamm, Donald L. // Contemporary Urology;Feb2005 Supplement, Vol. 17, p1 

    Presents information on the use of the bacillus Calmette-Gu�rin (BCG) vaccine for the treatment of bladder cancer and carcinoma in situ. History of BCG immunotherapy; Comparison of the effectiveness of BCG with intravesical chemotherapy; Findings of a study of patients with bladder tumors...

  • Efficacy and Safety of Bacille Calmette-Guerin Immunotherapy in Superficial Bladder Cancer. Lamm, Donald L. // Clinical Infectious Diseases;9/1/2000 Supplement 4, Vol. 31, pS86 

    Discusses the use of immunotherapy with intravesical bacille Calmette-Guerin (BCG) vaccines as an effective alternative approach to chemotherapy in the management of superficial bladder cancer. Expected long-term reduction in tumor recurrence, tumor progression and cancer mortality; Decrease in...

  • Mechanisms of Action of Intravesical Bacile Calmette-Guerin: Loca Immune Mechanisms. Prescott, Stephen; Jackson, Andrew M.; Hawkyard, Simon J.; Alexandroff, Anton B.; James, Keith // Clinical Infectious Diseases;9/1/2000 Supplement 4, Vol. 31, pS91 

    Discusses how Bacille Calmette-Guerin (BCG) vaccination is associated with the development of antituberculosis immunity but not necessarily with antitumor immunity. Local immune response to mycobacteria; Animal studies showing that an intact host immune system is required for the antitumor...

  • In Vitro Generation of Bacillus Calmette-Guerin-Activated Killer Cells. Brandau, S.; Bohle, A.; Thanhauser, A.; Ernst, M.; Mattern, T.; Ulmer, A.J.; Flad, H.-D. // Clinical Infectious Diseases;9/1/2000 Supplement 4, Vol. 31, pS94 

    Describes the induction of bacillus Calmette-Guerin (BCG)-activated killer (BAK) cells, which effectively lyse bladder tumor cells. Study of the immunostimulatory effects of BCG; Monoclonal antibodies that abolished BCG-mediated cytotoxicity; Beneficial effect of BCG on maintenance of the...

  • Genetics may provide clues to BCG non-response. Overmyer, Mac // Urology Times;Jul2000, Vol. 28 Issue 7, p19 

    Reports on the study conducted by researchers from the Hotel-Dieu de Quebec which revealed resistance to BCG immunotherapy among patients with bladder cancer. Role of the human natural resistance-associated macrophage protein 1 in the dampening or elimination of immunologic response; Allotype...

  • Spectrum of Bacille Calmette-Guerin (BCG) Infection after Intravesical BCG Immunotherapy. Gonzalez, Omar Y.; Musher, Daniel M.; Brar, Indira; Furgeson, Seth; Boktour, Maha R.; Septimus, Edward J.; Hamil, Richard J.; Graviss, Edward A. // Clinical Infectious Diseases;1/15/2003, Vol. 36 Issue 2, p140 

    Intravesical instillation of bacille Calmette-Gu�rin (BCG) effectively treats transitional cell carcinoma of the bladder. Occasionally, BCG infection complicates such treatment. In some patients, infection appears early (within 3 months after instillation) and is characterized by...

  • Quarter-dose BCG improves risk-benefit ratio. Guttman, Cheryl // Urology Times;Dec99, Vol. 27 Issue 12, p18 

    Reports that quarter-dose Bacille Calmette-Guerin has a clear ablative effect on superficial bladder cancer and also appears to minimize the risk of local adverse events compared with full-dose treatment. Phase II study by the European Organization for Research and Treatment of...

  • BCG.  // Reactions Weekly;10/29/2011, Issue 1375, p8 

    The article describes the case of a 72-year-old man who developed necrotising granulomatus epididymitis after receiving a six-week induction course of BCG for bladder cancer.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics